Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAS3351 |
Synonyms | |
Therapy Description |
TAS3351 is a 4th-generation EGFR inhibitor with activity against EGFR C797S and T790M, potentially reducing cell viability and tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3259). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAS3351 | TAS-3351|TAS 3351 | EGFR Inhibitor 4th gen 16 | TAS3351 is a 4th-generation EGFR inhibitor with activity against EGFR C797S and T790M, potentially reducing cell viability and tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3259). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05765734 | Phase Ib/II | TAS3351 | A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | 2 |